英国一例来自乌干达的恶性疟原虫感染患者治疗失败,其虫株对青蒿素和苯芴醇体外敏感性降低并携带基因变异
研究分离了一例标准治疗后确诊治疗失败的恶性疟原虫指示病例及可比旅行获得性英国疟疾病例的虫株,进行体外药物敏感性检测和6个耐药相关位点基因分型。该患者2022年从乌干达返回英国,两次完整疗程蒿甲醚-苯芴醇治疗均失败,虫株对青蒿素和苯芴醇敏感性显著降低,pfk13编码A675V和新型L145V变异。另1株2022年治疗失败病例虫株也显示敏感性降低并携带新型非螺旋桨区变异T349I。
要点
- 一例2022年从乌干达返回英国的恶性疟原虫患者两次完整疗程蒿甲醚-苯芴醇治疗均失败。
- 该患者虫株环状体存活率17.3%(95%CI 13.6%-21.1%),对青蒿素敏感性显著降低(P < .0001)。
- 该虫株对苯芴醇抑制50%生长的有效浓度为259.4 nM(95%CI 130.6-388.2 nM),敏感性显著降低(P = .001)。
核心结论
- 在一例有记录的从乌干达输入且蒿甲醚-苯芴醇治疗失败的病例中,确认存在编码L145V和A675V的pfk13突变。
- 对青蒿素和苯芴醇均敏感性降低的虫株可能在乌干达出现。
研究设计与样本
- 研究分离了一例标准治疗后确诊恶性疟原虫治疗失败的指示病例及可比旅行获得性英国疟疾病例的虫株。
- 对所有虫株进行体外药物敏感性检测和6个耐药相关位点基因分型,并与每个虫株供者的临床结局进行比较。
主要发现
- 一名2022年从乌干达返回英国的旅行者患恶性疟原虫疟疾,两次完整疗程蒿甲醚-苯芴醇治疗均失败。
- 该患者虫株对青蒿素敏感性显著降低,环状体存活率17.3%(95%CI 13.6%-21.1%),P < .0001。
- 该患者虫株对苯芴醇敏感性显著降低,抑制50%生长的有效浓度=259.4 nM(95%CI 130.6-388.2 nM),P = .001。
- 虫株基因分型鉴定出pfk13等位基因同时编码Pfk13螺旋桨结构域的A675V变异和新型非螺旋桨区L145V变异。
- 对另外6株乌干达来源的恶性疟原虫进行体外敏感性检测,发现另1株同样来自2022年治疗失败病例的虫株对青蒿素和苯芴醇敏感性降低;这些寄生虫不携带pfk13螺旋桨结构域变异,而携带新型非螺旋桨区变异T349I。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent cases of clinical failure in malaria patients in the United Kingdom (UK) treated with artemether-lumefantrine have implications for malaria chemotherapy worldwide. METHODS: Parasites were isolated from an index case of confirmed Plasmodium falciparum treatment failure after standard treatment, and from comparable travel-acquired UK malaria cases. Drug susceptibility in vitro and genotypes at 6 resistance-associated loci were determined for all parasite isolates and compared with clinical outcomes for each parasite donor. RESULTS: A traveler, who returned to the UK from Uganda in 2022 with Plasmodium falciparum malaria, twice failed treatment with full courses of artemether-lumefantrine. Parasites from the patient exhibited significantly reduced susceptibility to artemisinin (ring-stage survival, 17.3% [95% confidence interval {CI}, 13.6%-21.1%]; P < .0001) and lumefantrine (effective concentration preventing 50% of growth = 259.4 nM [95% CI, 130.6-388.2 nM]; P = .001). Parasite genotyping identified an allele of pfk13 encoding both the A675V variant in the Pfk13 propeller domain and a novel L145V nonpropeller variant. In vitro susceptibility testing of 6 other P. falciparum lines of Ugandan origin identified reduced susceptibility to artemisinin and lumefantrine in 1 additional line, also from a 2022 treatment failure case. These parasites did not harbor a pfk13 propeller domain variant but rather the novel nonpropeller variant T349I. Variant alleles of pfubp1, pfap2mu, and pfcoronin were also identified among the 7 parasite lines. CONCLUSIONS: We confirm, in a documented case of artemether-lumefantrine treatment failure imported from Uganda, the presence of pfk13 mutations encoding L145V and A675V. Parasites with reduced susceptibility to both artemisinin and lumefantrine may be emerging in Uganda.
引用
- van Schalkwyk DA, Pratt S, Nolder D, et al. Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine. Clin Infect Dis. 2024. PMID: 38019958. doi:10.1093/cid/ciad724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。